about
Rheumatoid Arthritis Disease Activity Is Determinant for ABCB1 and ABCG2 Drug-Efflux Transporters FunctionA mixed methods protocol to investigate medication adherence in patients with rheumatoid arthritis of White British and South Asian originAttitudes to early rheumatoid arthritis: changing patterns. Results of a survey.Validation of the GALS musculoskeletal screening exam for use in primary care: a pilot study.Should patients with recent onset rheumatoid arthritis be offered genetic screening?Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional studyJoint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.Treating rheumatoid arthritis to target: recommendations of an international task force.Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guideAmerican College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritisIncidence of corneal melting in association with systemic disease in the Yorkshire Region, 1995-7Cartilage and bone macromolecules in knee joint synovial fluid in rheumatoid arthritis: relation to development of knee or hip joint destruction.Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective studyOnly high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategySerum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical RemissionIntensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)[Rheumatoid arthritis].Remission by composite scores in rheumatoid arthritis: are ankles and feet important?Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States.Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugsPrediction of Large Joint Destruction in Patients With Rheumatoid Arthritis Using 18F-FDG PET/CT and Disease Activity Score.Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA studyThe clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of lifeAccess to rheumatologists among patients with newly diagnosed rheumatoid arthritis in a Canadian universal public healthcare system.The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis.The efficacy and safety of golimumab in the treatment of arthritis.Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years.Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life.Rheumatoid arthritis disease measurement: a new old idea.Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation.Exploitation of the IDO Pathway in the Therapy of Rheumatoid Arthritis.Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceStandardizing and personalizing the treat to target (T2T) approach for rheumatoid arthritis using the Patient-Reported Outcomes Measurement Information System (PROMIS): baseline findings on patient-centered treatment priorities.Patients with rheumatoid arthritis in clinical care.Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.Characterization of collagenase 3 (matrix metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis.Treating rheumatoid arthritisThe influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis.
P2860
Q28552801-810A64DA-4A5C-4245-81CF-6D826FA3DF7CQ30537006-D58BEECE-6F1D-43E2-BD5F-CF04388CD57CQ33206727-4A614E85-F0A3-4764-AAA1-5504468ED183Q33364285-4F030BC6-3BF8-4C77-B8D4-ED31EEB5E395Q33579027-4D05B167-5637-4DD8-A3DC-35CCF75CC018Q33956623-55605A29-F93F-4A13-A251-C3E9A670F3B3Q34033218-37E7E857-C36F-4FEF-8272-9C085986CBB2Q34240744-4DEDD2FE-3507-48D7-B1E8-2F8C6D7E704FQ34462557-9A8267E8-FE13-4B60-B49A-749A42F1AE90Q34550160-F7302B2E-7E7E-40BC-8F53-4A7A042EA10FQ35047250-D6C465C1-F766-4E88-9869-FDD4F518F017Q35177819-37A37DE4-C8F2-46C1-9D68-536084145503Q35311054-4C9A4005-8165-4C86-9E63-CE0CC4729611Q35547065-44079166-666E-4559-B201-1DAB2C63334CQ35547691-F2C7E74A-15B3-4850-8DAB-ADF1F7C8497CQ35548151-99C5457A-2D0B-4205-9A12-203A680FF005Q36188496-D254E9FE-52BF-4918-8B1A-792E9A75498AQ36204088-4E84A8E3-CD60-4EFA-BA24-DF001B74EC66Q36241682-BAED5FDE-EB2E-412C-95B6-D0279957D423Q36392370-ED97F256-D317-4BB3-A786-42D1F7228027Q36893038-C6186755-7F26-460C-A4C6-89D7E9A7EB0DQ37147818-F08FD7CB-5C81-412E-B445-081AF0B14E80Q37206225-2E13ADC7-E669-468E-B5D5-714CCFBF6B20Q37207061-E6C96735-576F-4D96-9265-A8F2ED09536EQ37358093-AFE03033-A18D-4F61-82C7-BD009D3D0DBFQ37552303-13126AAD-A6ED-4879-8018-115D0623F7B6Q37709364-BB97507E-33A0-4459-A36F-9E5C2E6B3274Q37760938-4495E9F5-BA55-4BCA-BAC7-BEE994C3012DQ37895016-F7F23A5C-F826-4406-B369-1D7A41EA9E7DQ37998604-6CF1932E-4D3C-485C-9E15-82C4F482B001Q38065766-2EA3BAF3-4F05-44E9-82D3-E77893A7D8D0Q38072667-45B45E34-497E-4A60-A281-46CA88C2E9E0Q38127176-7D761145-CE48-4D34-BD92-E3BEDAB0684FQ38476881-76239260-7FEC-4E30-9298-F020EE8D29E5Q38707741-A651DFFD-4E3A-45EF-ACC0-68E9DB9A740EQ41828498-4C5CE1DB-D6AD-4AB1-8F07-7595B649A3BEQ41917701-E8873AE5-F8DB-4D34-816D-6D5F0DC3E51DQ42474586-81AACE39-0462-4851-9862-0D4579BC1B82Q42592295-3DAA41B9-DF94-47F9-A5B5-1A1F31BA8376Q42611991-5C5615CF-E527-47FA-A37F-95968FC49982
P2860
description
1995 nî lūn-bûn
@nan
1995 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Early rheumatoid arthritis: time to aim for remission?
@ast
Early rheumatoid arthritis: time to aim for remission?
@en
Early rheumatoid arthritis: time to aim for remission?
@en-gb
Early rheumatoid arthritis: time to aim for remission?
@nl
type
label
Early rheumatoid arthritis: time to aim for remission?
@ast
Early rheumatoid arthritis: time to aim for remission?
@en
Early rheumatoid arthritis: time to aim for remission?
@en-gb
Early rheumatoid arthritis: time to aim for remission?
@nl
prefLabel
Early rheumatoid arthritis: time to aim for remission?
@ast
Early rheumatoid arthritis: time to aim for remission?
@en
Early rheumatoid arthritis: time to aim for remission?
@en-gb
Early rheumatoid arthritis: time to aim for remission?
@nl
P2860
P356
P1476
Early rheumatoid arthritis: time to aim for remission?
@en
P2093
P2860
P304
P356
10.1136/ARD.54.12.944
P407
P50
P577
1995-12-01T00:00:00Z
P5875
P6179
1041868727